Aaron D. Streblow

Aaron D. Streblow

Auto-generated profile, based on publicly available information

Aaron D. Streblow

Oregon Health & Science University School of Medicine, Portland, OR

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SAS. Kaleem Ahmed
S. Kaleem Ahmed
Nicole HaeseNicole Haese
Nicole Haese
JCJaden T. Cowan
Jaden T. Cowan
VPVibha Pathak
Vibha Pathak
OMOmar Moukha-Chafiq
Omar Moukha-Chafiq
APAshish K. Pathak
Ashish K. Pathak
A benzo[6]annulene, 4-(tert-butyl)-N-(3-methoxy-5,6,7,8-tetrahydronaphthalen-2-yl) benzamide (1a), was identified as an inhibitor against Chikungunya virus (CHIKV) with antiviral activity EC90 = 1.45 μM and viral titer reduction (VTR) of 2.5 log at 10 μM with no observed cytotoxicity (CC50 = 169 μM) in normal human dermal fibroblast cells. Chemistry efforts to improve potency, efficacy, and drug-like properties of 1a resulted in a novel lead compound 8q, which possessed excellent cellular antiviral activity (EC90 = 270 nM and VTR of 4.5 log at 10 μM) and improved liver microsomal stability. CHIKV resistance to an analog of 1a, compound 1c, tracked to a mutation in the nsP3 macrodomain. Further mechanism of action studies showed compounds working through inhibition of human dihydroorotate dehydrogenase in addition to CHIKV nsP3 macrodomain. Moderate efficacy was observed in an in vivo CHIKV challenge mouse model for compound 8q as viral replication was rescued from the pyrimidine salvage pathway.

1 June 2024 in JCO Precision Oncology
Verified
Journal Article
Open access
BKBen L. Kong
Ben L. Kong
JSJayne Stommel
Jayne Stommel
JKJamie M. Keck
Jamie M. Keck
DKDavid Kilburn
David Kilburn
ASAaron Streblow
Aaron Streblow
TPTanja B. Pejovic
Tanja B. Pejovic
Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.

15 March 2021 in Reproductive Sciences
Verified
Journal Article
Open access
PDF file
VRVictoria H J Roberts
Victoria H J Roberts
ASAaron D. Streblow
Aaron D. Streblow
JGJessica E. Gaffney
Jessica E. Gaffney
SRSamantha P. Rettke
Samantha P. Rettke
AFAntonio E. Frias
Antonio E. Frias
OSOv Daniel Slayden
Ov Daniel Slayden
We reported that consumption of a western-style diet (WSD) with and without hyperandrogenemia perturbed placental perfusion and altered levels of glucose transporter proteins in rhesus macaques. Based on that result, we hypothesized that placental glucose uptake would be dysregulated in this model. In this study, female rhesus macaques were assigned at puberty to one of four groups: subcutaneous cholesterol implants + standard chow diet (controls, C); testosterone implants + chow (T); cholesterol implants + a high-fat, WSD; and T+WSD. After ~6 years of treatment, animals were mated, and pregnancies were delivered by cesarean section at gestational day (G) 130 (the term is G168). Placental villous explants were immediately prepared for radiolabeled glucose assay. Linear glucose uptake was observed between 0 and 30 s. At 20 s, glucose uptake in placental villous explants did not differ across the four treatment groups with values as follows: C: 25.5 ± 6.33, T: 22.9 ± 0.404, WSD: 26.9.0 ± 3.71, and T+WSD: 33.0 ± 3.12 (mean ± SD expressed in pmol/mg). Unlike our prior experiment, glucose transporter expression was reduced in WSD placentas, and our in vitro functional assay did not demonstrate a difference in glucose uptake across the transporting epithelium of the placenta. Notably, maternal blood glucose levels were significantly elevated in animals chronically fed a WSD. This disparity may indicate differences in glucose utilization and metabolism by the placenta itself, as glucose transporter expression and circulating fetal glucose concentrations were comparable across all four groups in this pregnancy cohort.